Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
The Motley Fool
Viking Therapeutics' stock fell 18% after Merck signed a licensing deal for a competing weight-loss drug candidate. However, the article suggests that Viking still has a clear opportunity to succeed, with its own weight-loss drug candidates in development.
Continue Reading